BDBM375307 US10597387, Compound (I-6)::US9908872, Compound (I-6)

SMILES Cc1ccc(cc1NC(=O)c1cncc(c1)-c1cccs1)C(=O)Nc1cccc(c1)C(C)(C)C#N

InChI Key InChIKey=LELWDBPLERONSZ-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 375307   

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375307(US9908872, Compound (I-6) | US10597387, Compound (...)
Affinity DataIC50: 1.15E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375307(US9908872, Compound (I-6) | US10597387, Compound (...)
Affinity DataIC50: 29.9nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetHexokinase-4(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375307(US9908872, Compound (I-6) | US10597387, Compound (...)
Affinity DataIC50: 3.33E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/27/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375307(US9908872, Compound (I-6) | US10597387, Compound (...)
Affinity DataIC50: 1.15E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375307(US9908872, Compound (I-6) | US10597387, Compound (...)
Affinity DataIC50: 29.9nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2020
Entry Details
Go to US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM375307(US9908872, Compound (I-6) | US10597387, Compound (...)
Affinity DataIC50: 3.33E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK, and other kinases were obtained using an Invitrogen Select Screening...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2020
Entry Details
Go to US Patent